Bluebird Bio, Inc. (BLUE): David Davidson , Chief Medical Officer of Bluebird Bio, Inc. sold 1,000 shares on Jul 15, 2016. The Insider selling transaction was reported by the company on Jul 19, 2016 to the Securities and Exchange Commission. The shares were sold at $45.08 per share for a total value of $45,078.30 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 16, 2016, David Davidson (Chief Medical Officer) sold 1,000 shares at $40.11 per share price.On Jun 16, 2016, Philip D Gregory (Chief Scientific Officer) sold 2,931 shares at $39.52 per share price.Also, On Dec 9, 2015, Nick Leschly (CEO) purchased 9,682 shares at $51.75 per share price.On Dec 4, 2015, Eric Sullivan (Principal Accounting Officer) sold 416 shares at $81.13 per share price.
bluebird bio Inc: On Monday, Jul 18, 2016 heightened volatility was witnessed in bluebird bio Inc which led to swings in the share price. The shares opened for trading at $45.97 and hit $47.3737 on the upside , eventually ending the session at $46.56, with a gain of 1.60% or 0.735 points. The heightened volatility saw the trading volume jump to 5,58,859 shares. The 52-week high of the share price is $169.16 and the company has a market cap of $1,720 M . The 52-week low of the share price is at $35.37.
Company has been under the radar of several Street Analysts.bluebird bio Inc is Initiated by Cantor Fitzgerald to Hold. The Rating was issued on Jun 3, 2016.
bluebird bio Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. The Company’s products include Lenti-D LentiGlobin and CAR T Cells. The Company is developing Lenti-D to treat patients with CCALD (Childhood cerebral adrenoleukodystrophy) the severe form of ALD (Adrenoleukodystrophy). The Company is conducting a Phase II/III clinical study of Lenti-D in the United States. The Company is developing LentiGlobin to treat patients with b-thalassemia and severe SCD (sickle cell disease). The Company is conducting a Phase I/II clinical study of LentiGlobin. It also initiated a second Phase I/II clinical study in the United States Australia and Thailand for LentiGlobin. The Company is developing CAR T cell technology to deliver T cells engineered to kill the cancer.